ReveraGen
is a Maryland-based pharmaceutical company that researches and develops steroidal drugs for the treatment of DMD and chronic inflammatory disorders... Read moreReveraGen
is a Maryland-based pharmaceutical company that researches and develops steroidal drugs for the treatment of DMD and chronic inflammatory disorders... Read more
News
Nov 14, 2023
The Business Journals: Washington, D.C.
ReveraGen: Children's National Hospital spinout ReveraGen BioPharma gearing up for muscular dystrophy drug launch
Apr 25, 2023
Life Care News
ReveraGen: Vamorolone NDA mid-cycle review meeting by FDA completed
Jan 10, 2023
Pharmaceutical Business Review
ReveraGen: US FDA accepts Santhera, ReveraGen's vamorolone NDA to treat DMD
Nov 03, 2022
Muscular Dystrophy News
ReveraGen: Santhera, ReveraGen Seek FDA Approval of Vamorolone
Oct 10, 2022
StreetInsider
Press Release: ReveraGen : Santhera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress
Sep 01, 2022
Medthority
ReveraGen: JAMA Neurology publishes positive pivotal clinical trial , VISION-DMD, with vamorolone in Duchenne muscular dystrophy
Jun 09, 2022
FirstWord Pharma
ReveraGen: Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference
Apr 05, 2022
Muscular Dystrophy News
ReveraGen: Vamorolone Filing for FDA Approval for DMD Expected by June
Mar 29, 2022
FE Investegate
ReveraGen: Santhera Pharmaceuticals Holdi : Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
Mar 15, 2022
FirstWord Pharma
ReveraGen: Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
